News
Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.
8h
News-Medical.Net on MSNSemaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial showsA phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results